Who are Erbitux's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Vizimpro, Portrazza, Gilotrif, Tykerb, Tarceva, Iressa.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cetuximab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Erbitux — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Erbitux (cetuximab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Epidermal Growth Factor Receptor Antagonist [EPC]. Area: Oncology.

marketed Epidermal Growth Factor Receptor Antagonist [EPC] Epidermal growth factor receptor Oncology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Erbitux (cetuximab) — Imclone. Erbitux works by binding to the Epidermal Growth Factor Receptor (EGFR) on cancer cells, blocking the receptor's ability to stimulate cell growth and division.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Erbitux TARGET	cetuximab	Imclone	marketed	Epidermal Growth Factor Receptor Antagonist [EPC]	Epidermal growth factor receptor	2004-01-01
Vizimpro	dacomitinib	Pfizer	marketed		Epidermal growth factor receptor	2018-01-01
Portrazza	NECITUMUMAB	Eli Lilly Co	marketed	Epidermal Growth Factor Receptor Antagonist [EPC]	Epidermal growth factor receptor	2015-01-01
Gilotrif	afatinib	Boehringer Ingelheim	marketed	Kinase Inhibitor [EPC]	Epidermal growth factor receptor	2013-01-01
Tykerb	LAPATINIB	Novartis	marketed	Kinase Inhibitor	Epidermal growth factor receptor	2007-01-01
Tarceva	erlotinib	Osi Pharms	marketed	Kinase Inhibitor	Epidermal growth factor receptor	2004-01-01
Iressa	gefitinib	Pfizer Inc.	marketed	Kinase Inhibitor [EPC]	Epidermal growth factor receptor	2003-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Epidermal Growth Factor Receptor Antagonist [EPC] class)

· 1 drug in this class
Eli Lilly Co · 1 drug in this class
Imclone · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Erbitux — Competitive Intelligence Brief. https://druglandscape.com/ci/cetuximab. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing